<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281566</url>
  </required_header>
  <id_info>
    <org_study_id>CR003955</org_study_id>
    <secondary_id>CIS-INT-28</secondary_id>
    <nct_id>NCT01281566</nct_id>
  </id_info>
  <brief_title>A Study of Cisapride in Premature Infants With Feeding Problems</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2mg/kg q.i.d) for the Treatment of Feeding Intolerance in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Cisapride in improving feeding&#xD;
      problems in premature newborn infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind study where the identity of the treatment assigned (Cisapride or&#xD;
      placebo) will not be known to the patient's legal guardian or any study staff involved with&#xD;
      the study. Patients will be randomized (assigned by chance) to receive either the drug&#xD;
      Cisapride or a placebo (a placebo is identical in appearance to Cisapride but does not&#xD;
      contain Cisapride or any active drug) to see if Cisapride is effective in improving feeding&#xD;
      problems (referred to as feeding intolerance) in premature newborn infants who cannot&#xD;
      tolerate oral feeding by mouth or through a tube going directly to the stomach or intestine.&#xD;
      Patients will be given either cisapride at a dose of 0.2 mg/kg or placebo as a liquid&#xD;
      suspension through a tube from the nose to the stomach (referred to as a nasogastric tube) 15&#xD;
      minutes before feeding once every 6 hours (or 4 times a day referred to as a q.i.d.&#xD;
      schedule).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor request&#xD;
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start of study medication to full enteral feeding</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and type of adverse events</measure>
    <time_frame>Up to 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Infant, Premature</condition>
  <condition>Infant, Newborn</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisapride</intervention_name>
    <description>0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be hospitalized and on continuous cardiac monitoring for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Patient has demonstrated feeding intolerance as defined by the protocol&#xD;
&#xD;
          -  Patient's parent or legal guardian must sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently active significant cardiovascular disease, as determined by the&#xD;
             neonatologist/physician, including congenital heart disease and heart block (patent&#xD;
             ductus arteriosus without cardiac compromise at the time of randomization is&#xD;
             acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Weeks</minimum_age>
    <maximum_age>99 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Protfolio/CDT Leader</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
  </responsible_party>
  <keyword>Cisapride (Prepulsid)</keyword>
  <keyword>Feeding intolerance</keyword>
  <keyword>Enteral feeding</keyword>
  <keyword>Nasogastric tube</keyword>
  <keyword>Neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

